Naltrexone (Vivitrol)

Vivitrol (naltrexone ER injection) is covered only for FDA‑approved indications—treatment of alcohol dependence (with documented outpatient abstinence prior to initiation) and prevention of opioid relapse after completed detoxification—and coverage is limited to up to 12 months; non‑FDA indications are excluded. Approval requires meeting all baseline safety/eligibility criteria: documented diagnosis and abstinence or completed detox, opioid‑free ≥7 days (no current opioid use/physiologic dependence/acute withdrawal, negative naloxone challenge or urine screen), no acute hepatitis or hypersensitivity to product components, participation in a psychosocial program, and prior trial/failure or ineligibility for oral agents.

"For all approved indications, the individual meets ALL of the following criteria: Is NOT currently experiencing physiologic opioid dependence."